Skip to main content

Oncology · UK

Hormone therapy for breast cancer, by a consultant oncologist.

A properly planned 5–10 year endocrine treatment for hormone-receptor-positive breast cancer - tamoxifen, an aromatase inhibitor, ovarian suppression or a CDK4/6 inhibitor - with the side-effect plan built in from day one.

A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Indicative pricing

What private endocrine therapy costs in the UK.

Indicative ranges across our partner oncologists.

In short

A first consultation with a UK breast oncologist: £300–£500, tablets from £120 a year.

Item Indicative range
Initial oncology consultation £300–£500
Follow-up review £150–£250
Tamoxifen 20mg (annual) £120–£300
Aromatase inhibitor (annual) £150–£450
Goserelin / leuprorelin (per injection) £180–£320
Abemaciclib (Verzenios) - adjuvant, per month £2,400–£2,950
DEXA bone-density scan £180–£280

Endocrine tablets are available on the NHS via oncology and - for many patients - the drug cost is the smaller line item. Private cost is mostly the consultant’s time, the monitoring, and any add-ons such as CDK4/6 inhibitors that may or may not be funded by an insurer.

The problem

The right drug, the right duration, the right side-effect plan.

Endocrine therapy cuts recurrence and mortality by 30–40% (EBCTCG) - but only when you take it. Around a third to half of women stop within five years. Most of that is avoidable side-effect fatigue that a proper plan would have anticipated.

  • Not sure which drug?

    Tamoxifen or aromatase inhibitor, with or without ovarian suppression - informed by menopausal status, risk and side-effect profile.

  • 5 years or 10?

    Extending to 10 years benefits higher-risk disease (node-positive, Grade 3, high Ki-67). We make the case for or against, with the numbers.

  • Struggling with side effects?

    Joint pain, hot flushes, vaginal dryness, low mood - none of it is a reason to just stop. There are switches and add-ons for almost all of it.

When it helps

When endocrine therapy is the right treatment.

The clinical situations we see most, plus the red flag that means a same-week gynae referral rather than a routine appointment.

  • ER+ / PR+ early breast cancer

    Around three-quarters of breast cancers are hormone-receptor-positive on IHC. Endocrine therapy is the cornerstone of adjuvant treatment.

  • Premenopausal, standard-risk

    Tamoxifen 20mg daily for 5 years - cuts recurrence by roughly 40% and mortality by around 30%.

  • Premenopausal, high-risk

    Ovarian suppression (goserelin) added to tamoxifen - or with exemestane - improves outcome for younger, node-positive women (SOFT/TEXT).

  • Postmenopausal, standard-risk

    An aromatase inhibitor - anastrozole, letrozole or exemestane - for 5 years, superior to tamoxifen (ATAC, BIG 1-98, TEAM).

  • High-risk HR+ / HER2- disease

    Adjuvant abemaciclib (NICE TA810) for 2 years alongside endocrine therapy for node-positive high-risk disease (monarchE).

  • Germline BRCA1/2 mutation

    Adjuvant olaparib (NICE TA886) alongside endocrine therapy for high-risk BRCA-mutated HR+ disease.

  • Metastatic HR+ / HER2- disease

    First-line CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib) with an AI or fulvestrant - median overall survival now around 5+ years.

  • Red flag: post-menopausal bleeding

    Any vaginal bleeding on tamoxifen needs urgent gynae review - endometrial cancer risk is 2–3× baseline. Same-week, not "wait and see".

Treatment options

Tamoxifen is not the only option.

The drug classes on the table - what each does, and which patient it fits.

  • Tamoxifen (SERM)

    A selective oestrogen receptor modulator. 20mg daily for 5 years - or 10 years for higher-risk disease (aTTom, ATLAS trials).

  • Anastrozole / letrozole / exemestane

    Aromatase inhibitors for postmenopausal women. Block oestrogen production in fat and muscle. 5–10 years first-line for most.

  • Ovarian suppression

    Monthly or 3-monthly goserelin (Zoladex) or leuprorelin (Prostap). Or bilateral oophorectomy. Added for high-risk premenopausal disease.

  • AI + ovarian suppression

    Exemestane plus goserelin - TEXT trial showed superiority over tamoxifen + OS for high-risk younger women. Increasingly the UK preference.

  • Adjuvant CDK4/6 inhibitor

    Abemaciclib (Verzenios, NICE TA810) for 2 years alongside endocrine therapy for high-risk node-positive HR+/HER2- disease.

  • Adjuvant PARP inhibitor

    Olaparib (Lynparza, NICE TA886) for 1 year for germline BRCA1/2 mutation carriers with high-risk disease, alongside endocrine therapy.

  • Adjuvant bisphosphonate

    Zoledronic acid (Aclasta) for postmenopausal women - reduces bone-only recurrence and protects bone density on an AI.

  • Metastatic first-line

    CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib) with an AI or fulvestrant. Second line: alpelisib for PIK3CA-mutant, everolimus, elacestrant.

Safety and side effects

What to expect on treatment - honestly.

Endocrine therapy is well-tolerated for many, and hard work for others. The things worth planning are bone health, gynaecological surveillance on tamoxifen, and an honest, early conversation about anything that is affecting your daily life.

  • Menopausal symptoms are the norm

    Hot flushes, night sweats, mood and sleep disruption affect most women. Managed with lifestyle, SSRIs (venlafaxine), gabapentin or CBT - not just endured.

  • AI joint pain (arthralgia)

    The single commonest reason women stop an aromatase inhibitor.

  • Bone loss on an AI

    A baseline DEXA is mandatory before starting an AI, then every two years. Calcium, vitamin D, weight-bearing exercise and a bisphosphonate as needed.

  • Vaginal dryness and GSM

    Moisturisers (Replens, Yes), lubricants, vaginal DHEA and - with breast-MDT agreement - low-dose vaginal oestrogen. Symptomatic GSM is not something to accept in silence.

  • Endometrial risk on tamoxifen

    Tamoxifen raises endometrial cancer risk 2–3× baseline. Any post-menopausal bleeding needs same-week gynae review. Annual gynae review while on treatment.

  • VTE risk on tamoxifen

    Roughly double the baseline risk of DVT and pulmonary embolism. Stop before major surgery, and be alert to calf swelling or breathlessness.

  • Cardiovascular on an AI

    Small increases in hypertension and lipids. Annual BP and lipid check, statin if indicated - the AI is not usually the reason to stop.

  • Sexual function and libido

    Loss of libido, dryness and dyspareunia are common and legitimate reasons to raise the plan again - dose, drug and add-ons can all be reviewed.

  • Adherence is the biggest problem

    Roughly 30–50% of women stop endocrine therapy within 5 years - and survival is worse when they do. Say something before you stop.

Reading your treatment plan

Your endocrine plan in four parts. Read the last one first.

Whichever drug is chosen, the letter the oncologist writes keeps to the same shape.

A UK consultant oncologist reviewing a patient’s endocrine-therapy plan

A quiet reminder

Oncology language is precise and can read coldly - we translate it for you.

If you would like us to talk you through the plan before your review, just ask.

  1. 01 Header

    Diagnosis, receptor status and risk

    Stage, grade, node status, ER/PR/HER2, Ki-67 and any genomic assay (Oncotype DX, Prosigna) - the inputs that decide 5 vs 10 years.

  2. 02 Plan

    Which drug, which duration, which add-ons

    Tamoxifen or AI, with or without ovarian suppression, plus abemaciclib or olaparib if indicated. And the planned duration - 5 or 10 years.

  3. 03 Baseline

    Baseline tests and monitoring schedule

    DEXA, bloods, lipids and blood pressure at baseline, then a written schedule for the next 5–10 years so nothing gets forgotten.

  4. 04 Impression

    Side effects and adherence plan

    Read this first: what to expect, what to do about it, and how to reach the team when a symptom is affecting whether you take the next tablet.

Recognised by major UK insurers

BupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealix

Cover for oncology consultations and monitoring is usually funded when medically indicated.

Frequently asked

Everything we get asked about endocrine therapy.

Quick answers on drug choice, duration, CDK4/6 inhibitors, side effects and adherence.

  • What is hormone therapy for breast cancer?

    Endocrine therapy is a long-term systemic treatment that blocks the effect of oestrogen - or blocks oestrogen production - for hormone-receptor-positive breast cancers. Around 75% of breast cancers are ER+/PR+ on immunohistochemistry, and endocrine therapy is the cornerstone of their adjuvant treatment for 5–10 years.

  • Is this the same as HRT for menopause?

    No - it is the opposite. HRT (hormone replacement therapy) gives oestrogen back to relieve menopause symptoms. Endocrine therapy for breast cancer removes or blocks oestrogen to reduce cancer recurrence. See our separate page on HRT for menopause.

  • Tamoxifen or an aromatase inhibitor - which one?

    It depends on menopausal status. Premenopausal women usually start with tamoxifen, sometimes with ovarian suppression. Postmenopausal women usually start with an aromatase inhibitor (anastrozole, letrozole or exemestane), which is superior to tamoxifen in this group per ATAC, BIG 1-98 and TEAM.

  • How long do I take endocrine therapy for?

    Standard is 5 years. For higher-risk disease - node-positive, large primary, high Ki-67, Grade 3, young age at diagnosis - 10 years is often recommended (aTTom, ATLAS, MA.17). A shorter course is sometimes appropriate for very low-risk disease or intolerable side effects.

  • What is a CDK4/6 inhibitor and do I need one?

    CDK4/6 inhibitors (abemaciclib, palbociclib, ribociclib) block cell-cycle proteins that drive cancer growth. In the adjuvant setting, abemaciclib for 2 years alongside endocrine therapy is NICE-approved (TA810) for high-risk node-positive HR+/HER2- early breast cancer, based on the monarchE trial. In metastatic HR+/HER2- disease they are nearly universal first-line, alongside an AI or fulvestrant.

  • What are the main side effects?

    Menopausal symptoms (hot flushes, mood, sleep), joint pain (especially on AIs - the commonest reason for stopping), fatigue, vaginal dryness, weight gain, bone loss (AIs), a small increase in cardiovascular events (AIs), and - with tamoxifen - a 2–3× increase in endometrial cancer risk and 2× increase in VTE risk.

  • Can I use vaginal oestrogen if I am on endocrine therapy?

    Symptomatic genitourinary syndrome of menopause is common and legitimate. Non-hormonal options (Replens, Yes, lubricants) come first, then vaginal DHEA. Low-dose vaginal oestrogen can be considered with the agreement of the breast MDT - NICE supports it in symptomatic women despite earlier concerns.

  • What if I want to stop because the side effects are unbearable?

    Roughly 30–50% of women stop within 5 years and survival is worse when they do. There is almost always something to try - switching drugs, dose modification, add-on treatments for joint pain or hot flushes, or a planned break - before writing the treatment off.

Related

Looking for something else?